benign prostatic hyperplasia generally affects males above fourty years of age and has significant effect in overall quality of life (qol). this is one of the cause of millions of dollors in healthcare expenditure. alpha one adrenoreceptor blockers are frequently used for the benign prostatic enlargement because of their significant effect on storage and voiding symptoms, qol, flow rate and pos...

Therapeutic Class  Overview/Summary: The agents approved for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH) will be the focus of this review. The α-adrenergic blockers including, alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin, reduce smooth-muscle tone in the prostate and bladder neck decreasing lower urinary tract symptoms (LUTS) secondary to BPH. Alfuzo...

Copyright: © 2015 Tsai PC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. *Corresponding author: Chung-Jing Wang, Division of Urology, Department of Surgery, Saint Martin De Porres Hospital, Chiayi, Ta...

An HPLC-FLD method was developed using a surface response methodology for the quantification of silodosin in pharmaceuticals. The validated accuracy, precision, working range, reproducibility, limit detection, quantification, and robustness. Analytical Quality by Design (AQbD) strategy applied to develop an pharmaceuticals central composite design methodology. Excitation emission wavelengths wi...

Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS due to BPH. Alpha-adrenergic receptor blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH. They exhibit early onset of efficacy with regard to both symptoms and flow rate improvement, and this is...